Press release
AL Amyloidosis Market Report 2025-2034: Industry Overview, Trends, And Forecast Analysis
AL Amyloidosis Market Size
What Is the Current AL Amyloidosis Market Size and Its Estimated Growth Rate?
The market size of AL amyloidosis has seen a swift increase in the past few years. It's anticipated to escalate from $3.11 billion in 2024 to $3.52 billion in 2025, showcasing a compound annual growth rate (CAGR) of 13.2%. The historic progression in the market size can be accredited to the heightened awareness about AL amyloidosis amongst healare professionals, an increasing frequency of AL amyloidosis cases, growth in the elderly population, the development of diagnostic centers, and advancements in cardiac imaging.
In the coming years, the market size of AL amyloidosis is projected to experience swift expansion. It is predicted to surge to $5.74 billion by 2029, with a compound annual growth rate (CAGR) of 13.0%. The upswing for the projected period can be ascribed to an increase in mutation instances in blood cell DNA, enhancing healare infrastructure, a rising rate of multiple myeloma, the implementation of combination therapies, and the escalated use of high-dose chemotherapy. Major trends aligned for the forecast period incorporate progression in diagnostic methodologies, technological enhancements in drug distribution, improvements in blood examinations, the creation of targeted therapies, and the integration of artificial intelligence (AI) in diagnostic procedures.
Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20710
How Are Emerging Segments Shaping the AL Amyloidosis Market Landscape?
The AL amyloidosis market covered in this report is segmented -
1) By Treatment: Chemotherapy, Supportive Care, Surgery, Stem Cell Transplant, Targeted Therapy
2) By Drugs: Transthyretin Transport Inhibitor, Immunomodulatory Drugs, Monoclonal Antibodies, Proteasome Inhibitors, Other Drugs
3) By Route Of Administration: Intravenous, Oral
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Chemotherapy: Conventional Chemotherapy Agents, High-Dose Chemotherapy
2) By Supportive Care: Pain Management, Organ-specific Supportive Care (Cardiac, Renal)
3) By Surgery: Organ Transplantation, Debulking Surgery
4) By Stem Cell Transplant: Autologous Stem Cell Transplant, Allogeneic Stem Cell Transplant
5) By Targeted Therapy: Monoclonal Antibodies, Proteasome Inhibitors, Kinase Inhibitors
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20710&type=smp
Which Growth Factors Are Influencing AL Amyloidosis Market Expansion?
The increased prevalence of plasma cell disorders is projected to drive the growth of the AL amyloidosis market. Plasma cell disorders are diseases in which abnormal plasma cells create too many or abnormal antibodies, potentially inflicting damage to organs. The growing frequency of plasma cell disorders is credited to factors such as an elderly population, longer life expectancy, and progress in diagnostic technologies. AL amyloidosis arises from plasma cell disorders, particularly the overproduction of abnormal light chain proteins, which can result in the build-up of amyloid deposits in organs and tissues, further worsening the impact of plasma cell dyscrasias. For instance, in August 2024, as per the reports published by The American Cancer Society (ACS), a US-based non-profit organization, there will be around 35,780 new cases of multiple myeloma anticipated to be diagnosed (19,520 in men and 16,260 in women) in 2024, and about 12,540 deaths are estimated, with 7,020 in men and 5,520 in women. Therefore, the escalating prevalence of plasma cell disorders is fuelling the growth of the AL amyloidosis market.
Who Are the Dominant Players Across Different AL Amyloidosis Market Segments?
Major companies operating in the AL amyloidosis market are Johnson & Johnson, AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Astellas Pharma Inc., Genmab A/S, Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Prothena Corporation plc, BridgeBio Pharma Inc., Sorrento Therapeutics Inc., Ionis Pharmaceuticals Inc., Ultromics Ltd, Neurimmune AG, Immix Biopharma Inc., Oncopeptides AB, Attralus Inc.
What Are the Latest Developing Trends in the Acne Treatment Devices Market?
Key enterprises in the AL amyloidosis industry are concentrating on the creation of novel treatments like next-generation B-cell maturation antigen (BCMA)-directed CAR T-cell therapy, which offers improved therapeutic efficiency and patient prognosis. This next-generation therapy represents an advanced immunotherapy variant that involves modifying the patient's T cells to identify and combat BCMA found on cancer cells, particularly in multiple myeloma. For example, in September 2023, the U.S. Food and Drug Administration (FDA) granted approval to U.S. biopharmaceutical firm, Immix Biopharma Inc., for their NXC-201 application. This application was for the treatment of the potentially fatal blood condition Amyloid Light Chain (AL) Amyloidosis. Currently being tested in clinical trials, NXC-201 is a next-gen CAR-T cell therapy showing encouraging possibilities for AL amyloidosis treatment, with reports of a 100% hematologic response rate and organ function enhancement in patients unsuccessful with prior treatments.
Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/al-amyloidosis-global-market-report
Which Geographic Regions Are Expected to Dominate the AL Amyloidosis Market in the Coming Years?
North America was the largest region in the AL amyloidosis market in 2024. The regions covered in the AL amyloidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the AL Amyloidosis Market?
2. What is the CAGR expected in the AL Amyloidosis Market?
3. What Are the Key Innovations Transforming the AL Amyloidosis Industry?
4. Which Region Is Leading the AL Amyloidosis Market?
Why This Report Matters:
Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.
Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.
Efficient Research: Quickly identify market growth, leading players, and major segments.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release AL Amyloidosis Market Report 2025-2034: Industry Overview, Trends, And Forecast Analysis here
News-ID: 4067647 • Views: …
More Releases from The Business Research Company
Cardiac Ambulatory Monitoring Market Size Forecasted To Achieve 18.6 Billion By …
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What Is the Cardiac Ambulatory Monitoring Market Size and Projected Growth Rate?
The size of the cardiac ambulatory monitoring market has seen robust expansion in the past few years. There will be an increase from $14.17 billion in 2024 to $14.97 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 5.6%. This…
Biometric As A Service In Healare Market Anticipated To Witness Robust Growth, S …
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What Is the Current Biometric As A Service In Healare Market Size and Its Estimated Growth Rate?
With recent years seeing an exponential increase in the size of the biometric as a service in healare market, projections show that its value will inflate from $1.30 billion in 2024 to $1.61 billion in 2025 -…
Chronic Disease Prevalence Driving Demand For Advanced Care Solutions: A Key Dri …
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What Is the Current Artificial Intelligence-Powered Solutions For Elderly Care Market Size and Its Estimated Growth Rate?
In recent times, there has been a notable growth in the market size of AI-powered elderly care solutions. It is projected to surge from $25.64 billion in 2024 to $31.82 billion in 2025, sustaining a compound annual…
Adrenocortical Carcinoma Market Anticipated To Witness Robust Growth, Surpassing …
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What Is the Current Adrenocortical Carcinoma Market Size and Its Estimated Growth Rate?
The market size for adrenocortical carcinoma has been on a consistent rise in the past few years. The market, which is projected to be around $3.60 billion in 2024 is expected to increase to $3.77 billion by 2025, indicating a compound…
More Releases for Amyloid
Amyloid Peptides Market Size, Share, Development by 2024
Global Info Research offers a latest published report on Amyloid Peptides Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Amyloid Peptides players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Amyloid Peptides with respect to individual growth…
Islet Amyloid Polypeptide: Therapeutic Developments to Witness Growth
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Islet amyloid polypeptide (IAPP) or Amylin is a peptide hormone. This hormone is released from pancreatic beta cells following food intake to regulate blood glucose levels and act as a satiation signal. It inhibits insulin-stimulated glucose utilization and glycogen deposition in muscle. The molecules developed by companies in Phase II, Phase I and Preclinical stages…
Islet Amyloid Polypeptide: Therapeutic Developments to Witness Growth
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Islet amyloid polypeptide (IAPP) or Amylin is a peptide hormone. This hormone is released from pancreatic beta cells following food intake to regulate blood glucose levels and act as a satiation signal. It inhibits insulin-stimulated glucose utilization and glycogen deposition in muscle. The molecules developed by companies in Phase II, Phase I and Preclinical stages…
Familial Amyloid Cardiomyopathy Treatment Market Opportunity Analysis, 2018–20 …
Aggregation and deposition of mutant and wild-type transthyretin protein (TTR) in heart results in familial amyloid cardiomyopathy, which typically occur after age of 60. Familial amyloid cardiomyopathy is also known as hereditary cardiac transthyretin amyloidosis or hereditary amyloid cardiomyopathy. The protein transthyretin amyloid fibrils infiltrate the myocardium that leads to diastolic dysfunction from restrictive cardiomyopathy, which eventually result to heart failure. There are several mutation in TTR which are associated…
Familial Amyloid Neuropathies Pharmaceutical and Healthcare Analysis Information
Summary
Familial amyloid neuropathy is a slowly progressive condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body's organs and tissues. Symptoms include numbness, tingling, pins and needles in the feet and hands, weakness and pain in the arms and legs, loss of sensation, urinary retention, reduced sweating, ankle swelling, fatigue, nausea, weight loss, dizziness and fainting. Supportive treatment includes diuretics, calcium channel blockers,…
Islet Amyloid Polypeptide Market Trends & Forecast to 2022
HTF MI published a new industry research that focuses on Islet Amyloid Polypeptide market and delivers in-depth market analysis and future prospects of Global Islet Amyloid Polypeptide market. The study covers significant data which makes the research document a handy resource for managers, analysts, industry experts and other key people get ready-to-access and self-analyzed study along with graphs and tables to help understand market trends, drivers and market challenges. The…
